What is Roundtable 100?

Roundtable 100 is the weekly power ranking of the top 100 investable tech growth assets spanning crypto tokens, AI companies, and next-gen public markets. Rankings are published every Friday after market close and guided by a blue-ribbon committee of industry experts.

What assets are included in the Roundtable 100?

The Roundtable 100 includes crypto tokens, public tech stocks with growth potential, and mining companies. It excludes legacy or slow-growth companies, private companies, and non-liquid investments.

How are Roundtable 100 rankings scored?

Assets are scored across five dimensions: Safety (1x), Liquidity (1x), Leadership (1x), Innovation (1x), and Growth (2x double-weighted). Growth is intentionally double-weighted to reflect the mandate of identifying future dominance rather than present size.

What is the Roundtable 100 investment thesis?

The Roundtable 100 focuses on long-term growth across public equities and cryptocurrencies with a 5+ year time horizon, investing in future-defining technologies and the critical systems that enable them — prioritizing assets that function as rails, bottlenecks, and structural constraints within emerging digital and industrial ecosystems.

Recursion is advancing the first potential drug for rare disease FAP, discovered with AI

Name: Recursion is advancing the first potential drug for rare disease FAP, discovered with AI
Uploaded: 2026-06-17T19:11:06.702Z
Duration: 2 min 22 s
Channel: Recursion
Description: REC-4881 is the first clinical validation of Recursion’s AI-enabled drug discovery platform – positive Phase 1b/2 data for AI-identified drug REC-4881 in Familial Adenomatous Polyposis (FAP).

Recursion

Partner

Jun 17, 2026 7:11 PMPublished Jun 17, 2026 7:11 PM

Updated Jun 22, 2026 12:53 PM

REC-4881 is the first clinical validation of Recursion’s AI-enabled drug discovery platform – positive Phase 1b/2 data for AI-identified drug REC-4881 in Familial Adenomatous Polyposis (FAP).

This progressive rare disease – which affects more than 50,000 people in the US and EU5 – often begins in the teens and results in hundreds or thousands of polyps developing in the GI tract which have a 100% likelihood of becoming cancerous if not removed, requiring a lifetime of invasive surveillance and life-altering surgeries. There are currently no FDA-approved treatments. ▪️ Using the Recursion OS platform to analyze cell morphology, Recursion tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Recursion then used the full Recursion OS 2.0 platform — including ClinTech real-world evidence – to fully understand disease burden and guide clinical strategy, and expand patient eligibility for the trial. More Videos

Comments

Powered by RoundtableBuilt on infrastructure designed for real-time media. Learn more at RTB.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy